抗Mi2阳性皮肌炎以肌纤维坏死和巨噬细胞浸润为特征的严重肌损伤
研究比较了抗Mi2阳性与阴性成人皮肌炎患者的临床和肌肉病理表现,发现抗Mi2阳性患者肌酶升高更明显,肌活检显示更多坏死/变性肌纤维和内膜巨噬细胞浸润,类似免疫介导坏死性肌病,提示该亚型以严重肌损伤为特征。
要点
- 抗Mi2阳性皮肌炎患者治疗前肌酸激酶升高倍数显著高于抗Mi2阴性患者。
- 抗Mi2阳性患者肌活检坏死/变性肌纤维比例更高,且内膜巨噬细胞评分与IMNM相似。
- 抗Mi2阳性患者肺受累趋势较低,未见快速进展型间质性肺病。
核心结论
- 抗Mi2阳性皮肌炎是具有高度肌损伤的特定亚型,组织学标志为肌纤维坏死、内膜受累和巨噬细胞浸润。
主要发现
- 抗Mi2阳性患者治疗前肌酸激酶升高倍数中位数为16(IQR 7-37),显著高于抗Mi2阴性患者的3.5(IQR 1-9.9),P<0.001。
- 抗Mi2阳性患者肺受累比例为9.1%,抗Mi2阴性患者为30.4%,P=0.05,且抗Mi2阳性组无快速进展型间质性肺病病例。
- 抗Mi2阳性患者肌活检坏死/变性肌纤维平均比例为5.3%(标准差5%),高于抗Mi2阴性患者的0.8%(标准差1%),P<0.01,与IMNM患者的5.9%(标准差6%)相似(P>0.05)。
- 抗Mi2阳性患者内膜巨噬细胞评分平均为1.2(标准差0.9),与IMNM患者的1.3(标准差0.5)相似(P>0.05),而抗Mi2阴性患者较低,平均为0.4(标准差0.5),P<0.01。
关键数值与推荐
- 成人皮肌炎患者符合EULAR/ACR 2017分类标准。
- 抗Mi2阳性患者肌酸激酶升高倍数中位数16(IQR 7-37),抗Mi2阴性患者3.5(IQR 1-9.9),P<0.001。
- 抗Mi2阳性患者肺受累9.1% vs 抗Mi2阴性30.4%,P=0.05。
- 抗Mi2阳性患者坏死/变性肌纤维平均5.3%(5) vs 抗Mi2阴性0.8%(1),P<0.01;与IMNM 5.9%(6)相比P>0.05。
- 抗Mi2阳性患者内膜巨噬细胞评分平均1.2(0.9) vs IMNM 1.3(0.5),P>0.05;抗Mi2阴性0.4(0.5),P<0.01。
临床怎么用
- 对于抗Mi2阳性皮肌炎患者,应关注严重肌损伤,监测肌酶水平,肌活检可能显示类似IMNM的坏死和巨噬细胞浸润。
- 抗Mi2阳性患者肺受累风险可能较低,但仍需根据临床评估间质性肺病。
局限性
- 未报告治疗对病理表现的影响,且为横断面比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of our study was to investigate clinical and histopathological findings in adult DM patients positive for anti-Mi2 (anti-Mi2+) antibodies compared with DM patients negative for anti-Mi2 (anti-Mi2-). METHODS: Clinical data of adult DM patients, who fulfilled EULAR/ACR 2017 classification criteria, were gathered from electronic medical records of three tertiary Rheumatology Units. Histopathological study was carried out on 12 anti-Mi2+ and 14 anti-Mi2- muscle biopsies performed for diagnostic purpose. Nine biopsies from immune mediated necrotizing myopathy (IMNM) patients were used as control group. RESULTS: Twenty-two anti-Mi2+ DM [90.9% female, mean age 56.5 (15.7) years] were compared with 69 anti-Mi2- DM patients [71% female, mean age 52.4 (17) years]. Anti-Mi2+ patients presented higher levels of serum muscle enzymes than anti-Mi2- patients [median (IQR) creatine-kinase fold increment: 16 (7-37)vs 3.5 (1-9.9), P <0.001] before treatment initiation. Moreover, a trend towards less pulmonary involvement was detected in anti-Mi2+ DM (9.1% vs 30.4%, P =0.05), without any case of rapidly progressive interstitial lung disease. At muscle histology, anti-Mi2+ patients showed more necrotic/degenerative fibres than anti-Mi2- patients [mean 5.3% (5) vs 0.8% (1), P <0.01], but similar to IMNM [5.9% (6), P >0.05]. In addition, the endomysial macrophage score was similar between anti-Mi2+ and IMNM patients [mean 1.2 (0.9) vs 1.3 (0.5), P >0.05], whereas lower macrophage infiltration was found in anti-Mi2- DM [mean 0.4 (0.5), <0.01]. CONCLUSIONS: Anti-Mi2+ patients represent a specific DM subset with high muscle damage. Histological hallmarks were a higher prevalence of myofiber necrosis, endomysial involvement and macrophage infiltrates at muscle biopsy.
引用
- Fornaro M, Girolamo F, Cavagna L, et al. Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. Rheumatology (Oxford). 2021. PMID: 33249503. doi:10.1093/rheumatology/keaa739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。